Streetbeat News

Products Services

AMST

Amesite Inc. has announced a collaboration with partners to enhance clinical education by providing accredited continuing education for healthcare professionals through its AI-powered platform. This initiative aims to leverage Amesite's technology to improve the accessibility and quality of education for healthcare workers.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:39 pm

JSPR

Jasper Therapeutics announced significant progress in its clinical trials and financial achievements. The company completed a $50 million stock offering, extending its cash runway through Q3 2025. It received regulatory clearance in the US and EU for the BEACON and SPOTLIGHT studies of briquilimab in CSU and CIndU patients, respectively, and initiated a Phase 1 trial for briquilimab in myelodysplastic syndromes. Initial data from these studies are expected in 2024. Additionally, Jasper presented promising preclinical data at the AAAAI 2024 Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:39 pm

BTDR

Bitdeer Technologies has successfully tested its first Bitcoin mining chip, named Seal01, marking a significant milestone in the company's expansion into the cryptocurrency mining hardware market.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:36 pm

SMWB

Similarweb has acquired Admetricks, aiming to enhance its offerings in digital marketing and advertising analytics. The financial terms of the deal were not disclosed. Admetricks will continue to operate under its name as a Similarweb company.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:36 pm

ZVRA

Zevra Therapeutics announced the FDA has extended the review period for its new drug application for Arimoclomol, a treatment for Niemann-Pick Disease Type C. The new PDUFA action date is set for September 21, 2024, with plans for an advisory committee meeting. The extension is due to the FDA needing more time to review additional analyses provided by Zevra.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:33 pm

INDP

Indaptus Therapeutics announced positive results from the second cohort of its Phase 1 trial for Decoy 20, leading to the initiation of a multi-dose cohort. The data from the single dose cohort is expected to be published at a scientific conference in 2024.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:33 pm

NVDA

U.S. markets closed higher on Friday, led by Nvidia and a tech rally, despite a drop in ISM manufacturing PMI and consumer sentiment. Asian markets were mixed, with Japan's Nikkei reaching a record high. European markets and U.S. futures saw declines. Commodities showed mixed performance with crude oil slightly down and natural gas up. Nvidia's performance stands out due to the growing demand for artificial intelligence.

Portfolio Pulse from Akanksha Bakshi

March 04, 2024 | 12:29 pm

SVFD

Save Foods announced its subsidiary, Plantify Foods, which it owns 23% of, has secured a new retailer, expanding its market presence in Israel. This development could enhance Save Foods' market position and financial performance.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:25 pm

XRTX

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, has announced the completion of a second tranche closing, raising CAD $224,850 through a prospectus supplement and a concurrent private placement. This funding is part of a previously announced offering aimed at developing therapies for progressive kidney disease. The private placement included international subscribers, contributing CAD $99,000 to the total raised funds.

Portfolio Pulse from Charles Gross

March 04, 2024 | 12:21 pm

IRDM

Iridium Communications Inc. has announced an agreement to acquire the remaining approximately 80% stake in Satelles for about $115 million. This acquisition will introduce Satellite Time and Location as a new business line for Iridium, led by Satelles CEO Dr. Michael O'Connor. Iridium, which already owned about 20% of Satelles from previous investments, will assume all rights to Satelles' patent portfolio. The company expects the Iridium STL business to generate over $100 million in service revenue annually by 2030, in addition to revenue from equipment and engineering. The acquisition will be financed through an addition to Iridium's term loan.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:11 pm